JP2018512402A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512402A5 JP2018512402A5 JP2017548142A JP2017548142A JP2018512402A5 JP 2018512402 A5 JP2018512402 A5 JP 2018512402A5 JP 2017548142 A JP2017548142 A JP 2017548142A JP 2017548142 A JP2017548142 A JP 2017548142A JP 2018512402 A5 JP2018512402 A5 JP 2018512402A5
- Authority
- JP
- Japan
- Prior art keywords
- immunoconjugate
- immune complex
- subject
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562132251P | 2015-03-12 | 2015-03-12 | |
| US62/132,251 | 2015-03-12 | ||
| US201562267386P | 2015-12-15 | 2015-12-15 | |
| US62/267,386 | 2015-12-15 | ||
| PCT/US2016/022085 WO2016145354A1 (en) | 2015-03-12 | 2016-03-11 | Dosing strategies for targeting epcam positive bladder cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018512402A JP2018512402A (ja) | 2018-05-17 |
| JP2018512402A5 true JP2018512402A5 (enExample) | 2019-04-18 |
| JP6847846B2 JP6847846B2 (ja) | 2021-03-24 |
Family
ID=56879327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017548142A Expired - Fee Related JP6847846B2 (ja) | 2015-03-12 | 2016-03-11 | Ｅｐｃａｍ陽性膀胱癌を標的とする投薬戦略 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10583198B2 (enExample) |
| EP (1) | EP3268041A4 (enExample) |
| JP (1) | JP6847846B2 (enExample) |
| CN (1) | CN107580501A (enExample) |
| AU (1) | AU2016228760B2 (enExample) |
| CA (1) | CA2979400A1 (enExample) |
| HK (1) | HK1249731A1 (enExample) |
| WO (1) | WO2016145354A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2829283T (pt) | 2003-04-30 | 2017-09-08 | Univ Zuerich | Método para tratamento do cancro utilizando uma imunotoxina |
| PL3052525T3 (pl) | 2013-10-02 | 2020-03-31 | Viventia Bio Inc. | Przeciwciała anty- EpCAM i sposoby wykorzystania |
| WO2016145349A1 (en) | 2015-03-12 | 2016-09-15 | Viventia Bio Inc. | Methods of treatment for epcam positive bladder cancer |
| CA2979400A1 (en) | 2015-03-12 | 2016-09-15 | Viventia Bio Inc. | Dosing strategies for targeting epcam positive bladder cancer |
| US11497781B2 (en) | 2016-03-10 | 2022-11-15 | Cg Oncology, Inc. | Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor |
| EP3610026B1 (en) | 2017-04-14 | 2025-05-14 | CG Oncology, Inc. | Cg0070 for treating bcg resistant bladder carcinoma in situ |
| WO2023222024A1 (en) * | 2022-05-18 | 2023-11-23 | Bj Bioscience Inc. | Bispecific antibodies targeting epcam and cd3 |
| CN115109164A (zh) * | 2022-06-07 | 2022-09-27 | 博际生物医药科技(杭州)有限公司 | 靶向epcam和cd3的双特异性抗体 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5082767A (en) | 1989-02-27 | 1992-01-21 | Hatfield G Wesley | Codon pair utilization |
| IL98528A0 (en) | 1990-06-21 | 1992-07-15 | Merck & Co Inc | Pharmaceutical compositions containing hybrid for killing bladder cancer cells |
| US20030148463A1 (en) | 1997-04-14 | 2003-08-07 | Micromet Ag | Novel method for the production of anti-human antigen receptors and uses thereof |
| GB9709421D0 (en) | 1997-05-10 | 1997-07-02 | Zeneca Ltd | Chemical compounds |
| US6680296B1 (en) | 1997-06-06 | 2004-01-20 | Tanox Pharma B.V. | Type-1 ribosome-inactivating protein |
| ES2221717T3 (es) | 1997-12-08 | 2005-01-01 | Emd Lexigen Research Center Corp. | Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general. |
| US6280742B1 (en) | 1998-06-17 | 2001-08-28 | Zonagen, Inc. | Methods and materials for the treatment of prostatic carcinoma |
| ES2308981T3 (es) | 1999-04-09 | 2008-12-16 | Universitat Zurich | Metodo para la estabilizacion de las inmunoglobulinas hibridas o fragmentos de inmunoglobulina y fragmentos anti-egp-2-scfv estabilizado. |
| GB9911569D0 (en) | 1999-05-18 | 1999-07-21 | Oxford Biomedica Ltd | Antibodies |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| BR0209177A (pt) | 2001-05-03 | 2004-10-05 | Merck Patent Gmbh | Anticorpo especìfico a tumor recombinante e uso do mesmo |
| US20030148950A1 (en) | 2001-10-09 | 2003-08-07 | Li Xin | Kringle domain 1 of human hepatocyte growth factor and uses therefor |
| CN1604966A (zh) | 2001-10-15 | 2005-04-06 | 免疫医疗公司 | 直接靶定的结合蛋白 |
| US20040022726A1 (en) * | 2002-06-03 | 2004-02-05 | Goldenberg David M. | Methods and compositions for intravesical therapy of bladder cancer |
| SI21272A (sl) | 2002-07-31 | 2004-02-29 | LEK farmacevtska dru�ba d.d. | Sintetski gen za humani granulocitne kolonije stimulirajoči dejavnik za ekspresijo v E. coli |
| CA2424255A1 (en) | 2003-03-26 | 2004-09-26 | Claudio Di Paolo | Immunotoxins |
| PT2829283T (pt) | 2003-04-30 | 2017-09-08 | Univ Zuerich | Método para tratamento do cancro utilizando uma imunotoxina |
| CA2560278C (en) | 2004-03-19 | 2012-11-20 | Matthew Baker | Modified bouganin proteins, cytotoxins and methods and uses thereof |
| PL1766017T3 (pl) | 2004-06-10 | 2015-08-31 | Viventia Bio Inc | Przeciwciało specyficzne wobec nowotworu |
| US20090171317A1 (en) | 2006-03-10 | 2009-07-02 | Ebrahim Versi | Self-Catheterization Device To Administes Compounds To The Bladder |
| WO2008052322A1 (en) | 2006-10-30 | 2008-05-08 | Viventia Biotech Inc. | Immunotoxγn fusions comprising an antibody fragment and a plant toxin linked by protease cleavable linkers |
| WO2008128330A1 (en) | 2007-04-19 | 2008-10-30 | Viventia Biotech Inc. | Optimized nucleotide sequences of vb6-845 for expression of recombinant proteins |
| CA2700815A1 (en) | 2007-09-27 | 2009-04-02 | Viventia Biotech Inc. | Optimized nucleic acid sequences for the expression of vb4-845 |
| CA2618163A1 (en) | 2008-02-07 | 2009-08-07 | K. W. Michael Siu | Head and neck cancer biomarkers |
| MX2011010469A (es) | 2009-04-08 | 2012-03-14 | Deutsches Krebsforsch | Radicales de enlace al objetivo, armados con amatoxina para el tratamiento del cancer. |
| GB0909904D0 (en) | 2009-06-09 | 2009-07-22 | Affitech As | Product |
| WO2011116387A1 (en) | 2010-03-19 | 2011-09-22 | Tetragenetics, Inc. | Production of aglycosylated monoclonal antibodies in ciliates |
| WO2012178173A1 (en) | 2011-06-24 | 2012-12-27 | Centrose, Llc | Extracellular targeted drug conjugates |
| CA2909153A1 (en) | 2013-04-12 | 2014-10-16 | Viventia Bio Inc. | Compositions and methods for detection and treatment of hepatocellular carcinoma |
| PL3052525T3 (pl) | 2013-10-02 | 2020-03-31 | Viventia Bio Inc. | Przeciwciała anty- EpCAM i sposoby wykorzystania |
| CA2979400A1 (en) | 2015-03-12 | 2016-09-15 | Viventia Bio Inc. | Dosing strategies for targeting epcam positive bladder cancer |
| WO2016145349A1 (en) | 2015-03-12 | 2016-09-15 | Viventia Bio Inc. | Methods of treatment for epcam positive bladder cancer |
| WO2017040801A2 (en) | 2015-09-02 | 2017-03-09 | Viventia Bio Inc. | Methods for making and using an immunoconjugate for the treatment of cancer |
-
2016
- 2016-03-11 CA CA2979400A patent/CA2979400A1/en active Pending
- 2016-03-11 JP JP2017548142A patent/JP6847846B2/ja not_active Expired - Fee Related
- 2016-03-11 EP EP16762631.6A patent/EP3268041A4/en not_active Withdrawn
- 2016-03-11 HK HK18108761.0A patent/HK1249731A1/zh unknown
- 2016-03-11 CN CN201680027485.0A patent/CN107580501A/zh active Pending
- 2016-03-11 AU AU2016228760A patent/AU2016228760B2/en not_active Ceased
- 2016-03-11 US US15/557,369 patent/US10583198B2/en active Active
- 2016-03-11 WO PCT/US2016/022085 patent/WO2016145354A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016528247A5 (enExample) | ||
| JP2014158469A5 (enExample) | ||
| JP2018518454A5 (enExample) | ||
| JP2016520082A5 (enExample) | ||
| JP2020508317A5 (enExample) | ||
| JP2017506217A5 (enExample) | ||
| JP2016094424A5 (enExample) | ||
| JP2019519499A5 (enExample) | ||
| RU2019106663A (ru) | Комбинированная терапия рака | |
| JP2013520442A5 (enExample) | ||
| JP2012501626A5 (enExample) | ||
| JP2009533367A5 (enExample) | ||
| JP2018505177A5 (enExample) | ||
| JP2011506483A5 (enExample) | ||
| JP2016519650A5 (enExample) | ||
| JP2015534579A5 (enExample) | ||
| JP2015517529A5 (enExample) | ||
| JP2020510039A5 (enExample) | ||
| JP2018529661A5 (enExample) | ||
| WO2016090024A4 (en) | Combination therapy for treatment of cancer | |
| WO2017042352A1 (en) | Dosing regimens for anti-tf-antibody drug-conjugates | |
| JP2019524713A5 (enExample) | ||
| EP3896089A1 (en) | Use of il-15 protein complex joint pd-l1 antibody for treating tumor diseases | |
| JP2015528802A5 (enExample) | ||
| JP2018509423A5 (enExample) |